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The present invention provides compounds and methods
that can be used to convert the intermediate halomethyl
ketones (HMKs), e.g., chloromethyl ketones, to the corre-
sponding S,S- and R,S-diastereomers. More particularly, the
present invention provides: (1) reduction methods; (2) inver-
sion methods; and (3) methods involving the epoxidation of
alkenes. Using the various methods of the present invention,
the R,S-epoxide and the intermediary compounds can be
prepared reliably, in high yields and in high purity.
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nitromethane, cyanide (see, Shibata, et aI., Chern. Pharrn.
Bull., 46(4):733-735 (1998) or carbene sources (see, Liu, et
aI., Org. Proc. Res. Dev., 1:45-54 (1997). Instability and
difficulty in preparation of the aldehyde make these routes
5 undesirable (see, Beaulieu, et aI., J. Org. Chern.,
62:3440-3448 (1997).
45
Other routes that have been published, but not commer-
cialized are illustrated in FIG. 1.
One of the best reagents that can be used to add a single
carbon to amino acids is diazomethane because it gives high
yields and few side-products. In addition, diazomethane
reactions are very clean, generating only nitrogen as a
by-product. HIV inhibitor molecules need high purity
because of the high daily doses required. As such, diaz-
omethane is an ideal reagent for making high purity com-
pounds. In spite of the documented hazards of
diazomethane, processes have recently been developed that
permit the commercial scale use of diazomethane to convert
amino acids to the homologous chloromethyl ketones (see,
U.S. Pat. No. 5,817,778, which issued to Archibald, et aI. on
Oct. 6, 1998; and U.S. Pat. No. 5,854,405, which issued to
Archibald, et aI. on Dec. 29, 1998). FIG. 2 illustrates
examples of HIV protease inhibitors wherein the central
linking group can be synthesized by the commercial use of
diazomethane. FIG. 3 illustrates a general reaction scheme
that can be used to prepare the S,S-epoxide compound using
diazomethane.
The most useful amino acid isosteres are based on phe-
nylanaline. The key intermediate in the synthesis of Sequi-
nivir® (Roche) and Aprenavir® (Glaxo Wellcome) is the
(S,S -)N-t-bu toxycarbonyl-1 ,2-epoxy-4-phenyl-3-
butanamine. Several other protease inhibitors, such as those
50 described in Chen, et aI. (J. Med. Chern., 39:1991-2007
(1996) or those under development (e.g., BMS-234475 or
BMS-232623), use the diastereomeric (R,S-) N-t-
butoxycarbonyl-1 ,2-epoxy-4-pheny1-3-butanamine.
Beginning with readily available (L)-phenylanaline, one
is able to manufacture N-t-butoxycarbonyl-1-chloro-2-keto-
4-phenylbutanamine (called "chloroketone" or "CMK")
using the methods described in the literature (see, e.g.,
Parkes, et aI., J. Org. Chern., 59:3656-3664 (1994); Shaw,
Methods in Enzymology, 11:677-686 (1967); and Dufour, et
60 aI., J. Chern. Soc. Perkin Trans. I, 1895-1899 (1986), the
teachings of which are incorporated herein by reference).
However, what are needed in the art are methods that allow
one to produce reliably and in high-yields either
diastereomer, i.e., the S,S or the R,S, from the common
65 chloroketone starting material (see, FIG. 4). Quite
surprisingly, the present invention fulfills this and other
needs.
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BACKGROUND OF THE INVENTION
1
CLEAN, HIGH-YIELD PREPARATION OF S,S
AND R,S AMINO ACID ISOSTERES
CROSS-REFERENCE TO RELATED
APPLICATION
t-BocHN
t-BocHN
Human immunodeficiency virus (HIV), the causative
agent of acquired immunodeficiency syndrome (AIDS),
encodes three enzymes, including the well-characterized 15
proteinase belonging to the aspartic proteinase family, the
HIV protease. Inhibition of this enzyme has been regarded
as a promising approach for treating AIDS. Hydroxyethy-
lamine isosteres have been extensively utilized in the syn-
thesis of potent and selective HIV protease inhibitors. 20
However, this modern generation of HIV protease inhibitors
has created an interesting challenge for the synthetic organic
chemist. Advanced x-ray structural analysis has allowed for
the design of molecules that fit closely into active sites on
enzymes creating very effective drug molecules. 25
Unfortunately, these molecules, designed by molecular
shape, are often difficult to produce using conventional
chemistry.
The modem generation of HIV inhibitors has structural
similarities in a central three-carbon piece containing two 30
chiral carbons that link two larger groups on each side (see,
e.g., Parkes, et aI., J. Org. Chern., 59:3656-3664 (1994).
Numerous synthetic routes to these isosteres have been
developed. As illustrated below, a common strategy to
prepare the linking group starts with an amino acid, such as 35
phenylalanine, to set the chirality of the first carbon. Then,
the linking group is completed by a series of reactions
including a one-carbon homologization during which the old
amino acid carbon is transformed into a hydroxy-
functionalized carbon having the correct chirality. However, 40
the commercial production of isosteres by this method
presents serious challenges, generally requiring low-
temperature organometallic reactions (Ghosh, et aI., J. Org.
Chern., 62:6080-6082 (1997) or the use of exotic reagents.
This application claims the benefit of U.S. Provisional
Patent Application Serial No. 60/132,278, filed May 3,1999,
which is incorporated herein by reference in its entirety for
all purposes.
A second approach, which is illustrated below, is to
convert the amino acid to an aldehyde and to add the carbon
by use of a Wittig reaction to give an olefin (see, Luly, et aI.,
J. Org. Chern., 52:1487-1492 (1987). The olefin is then
epoxidized. Alternatively, the aldehyde can be reacted with
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SUMMARY OF THE INVENTION
4
20
The present invention provides compounds and methods
that can be used to convert the intermmediate halomethyl
ketones (HMKs), e.g., chloromethyl ketones, to the corre- 5
sponding S,S- and R,S-diastereomers. It is these chiral
centers that determine the chiral centers in the HIV protease
inhibitor and, thus, the efficacy of the drug. As explained
herein, the present invention provides (1) reduction meth-
ods; (2) inversion methods; and (3) methods for preparing 10
alkenes that, in turn, can undergo epoxidation reactions to
form the desired R,S-epoxide. Using the various methods of
the present invention, the R,S-epoxide and the intermediary
compounds can be prepared reliably, in high yields and in
high purity. 15
As such, in one embodiment, the present invention pro-
vides a method for selectively preparing an R,S-halomethyl
alcohol (R,S-HMA) compound having the following general
formula:
25
(I)
with a reducing agent to form an S,S-halomethyl alcohol
(S,S-HMA) compound having the following general
formula:
(II)
(b) contacting the S,S-HMA compound of Formula II
with a member selected from the group consisting of
arylsulfonyl halides and alkylsulfonyl halides in the
presence of an amine to form an S,S-halomethyl sul-
fonyl (S,S-HMS) compound having the following gen-
eral formula:
the method comprising: reducing a compound having the
following general formula:
30
(III)
(IV)
(c) contacting the S,S-HMS compound of Formula III
with an acetate in the presence of a phase transfer
catalyst and water to form an R,S-halomethyl acetate
(R,S-HMAc) compound having the following general
formula:
and (d) contacting the R,S-HMAc compound of Formula IV
with an alkali metal base to form the R,S-epoxide. In the
above formulae, R l is an amino acid side chain (e.g., a
benzyl group, an S-phenyl group, an alkyl group, a para-
nitrobenzene group, etc.); R2 is a blocking or protecting
group; Xl is a leaving group (i.e., a halo group, such as
chloro); R3 is a functional group including, but not limited
to, arylsulfonyls and alkylsulfonyls (e.g., a mesyl group, a
60 tosyl group, a trifiate group, a nosyl group, etc.); and R4 is
an acyl group derived from the acetate (e.g., an acetyl
group).
50
with a non-chelating, bulky reducing agent to form the
R,S-HMA compound. In the above formulae, R1 is an
amino acid side chain (e.g., a benzyl group, an
S-phenyl group, an alkyl group and a para-nitrobenzene
group, etc.); R2 is a blocking or protecting group (e.g., 40
Boc, Cbz, Moc, etc.); and Xl is a leaving group (e.g.,
a halo group, such as chloro). In a presently preferred
embodiment, the non-chelating, bulky reducing agent
is a member selected from the group consisting of
lithium aluminum t-butoxyhydride (LATBH), sodium 45
tris-t-butoxyborohydride (STBH). In another presently
preferred embodiment, the reduction is carried out in a
solvent such as diethyl ether. Once formed, the R,S-
HMA can be reacted with an alkali metal base to form
an R,S-epoxide.
In another aspect, the present invention provides inver-
sion methods that can be used to selectively prepare the
R,S-epoxide. In one embodiment of the inversion method,
R,S-epoxide is prepared by a four step process. More
particularly, in one embodiment of the inversion method, the 55
present invention provides a method for preparing an R,S-
epoxide having the following general formula:
35
the method comprising: (a) reducing a halomethyl ketone 65
(HMK) compound having the following general for-
mula:
In another embodiment of the inversion method, the
present invention provides a method for preparing an R,S-
epoxide compound having the following general formula:
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BRIEF DESCRIPTION OF THE DRAWINGS
the method comprising: (a) contacting an S,S-halomethyl
sulfonyl (S,S-HMS) compound having the following general 10
formula:
and (c) dehalohydroxylating a compound of Formula III
to form the alkene. In the above formulae, R l , R2, and
Xl are as defined above. Once prepared, the alkene can
be converted to the R,S-epoxide using, for example,
m-chloroperbenzoic acid.
Other features, objects and advantages of the invention
15 and its preferred embodiments will become apparent from
the detailed description which follows.
20
with a carbamate-forming acetate to form a cyclic carbam-
ate; and (b) contacting the cyclic carbamate with an alkali
metal base to form the R,S-epoxide. In the above formulae,
R\ R2 , R3 and Xl are as defined above. In a presently
preferred embodiment, the carbamate-forming acetate is
sodium trichloroacetate.
In yet another aspect, the present invention provides a
method for preparing R,S-epoxide by the epoxidation of an
alkene. More particularly, the present invention provides a
method for preparing an alkene having the following general
formula:
FIG. I illustrates various routes that can be used to
prepare an R,S-epoxide. FIG. leA) illustrates a method
described by Liu, et aI., Org. Proc. Res. Dev., 1:45-54
(1997); and Beaulieu, et al.,J. Org. Chern., 62:3441 (1997).
FIG. I(B) illustrates a method described by Parkes, et al. J.
25 Org. Chern., 59:3656-3664 (1994).
FIG. 2 illustrates examples of HIV protease inhibitors
where the central linking group can be synthesized by
commercial use of diazomethane.
FIG. 3 illustrates a general reaction scheme that can be
30 used to prepare the epoxide compound.
FIG. 4 illustrates the two diastereomers that can be
formed from the common chloroketone starting material,
i.e., S,S-epoxide and R,S-epoxide.
The present invention provides various compounds and
40 methods that can be used to prepare both reliable and in high
yields either diastereomer, i.e., the S,S- or the R,S-, from the
common halomethyl ketone (e.g., chloromethyl ketone)
starting material. More particularly, as explained herein in
greater detail, the present invention provides (1) reduction
45 methods; (2) inversion methods, and (3) methods involving
the epoxidation of alkenes.
(IV)
H
R~
or ~,
R2HN
the method comprising: (a) contacting a compound hav-
ing the following general formula:
35 DETAILED DESCRIPTION OF THE
INVENTION AND PREFERRED
EMBODIMENTS
A. THE REDUCTION METHODS
A variety of reducing agents can be used to reduce a
50 halomethyl ketone (HMK) to a halomethyl alcohol (HMA)
(see, Table I). However, under most conditions, the pre-
dominate diastereomer is the 2S,3S-HMA. For instance,
reduction of HMK with sodium borohydride in ethanol
(Chen, et al.,J. Med. Chern., 39:1991-2007 (1996) produces
55 a 1:4 mixture of R,S:S,S HMA in near quantitative yield.
Moreover, the reduction of HMK with aluminium isopro-
poxide in isopropanol can give ratios as high as 1: 18 in favor
of the S,S-isomer (see, U.S. Pat. Nos. 5,684,176 and 5,847,
144, both of which issued to Hilpert). Thus, commercial
60 routes to S,S-HMA are easily achieved.
In contrast, the preparation of the R,S-isomer is much
more difficult. A slight increase in the R,S-HMAS,S-HMA
ratio is achieved when the reaction solvent, ethanol, is
replaced with THE Further enhancement in the R,S-
HMAS,S-HMA ratio is obtained when the reduction is
carried out in the presence of CeCl3 (Barluenga, et aI., J.
Org. Chern., 62:5974(1997); but even then the ratio of
(I)
(II)
(b) reducing a compound of Formula II with a reducing 65
agent to form a compound having the following general
formula:
with a hydrohalo acid to form a compound having the
following general formula:
US 6,605,732 Bl
7 8
with a non-chelating, bulky reducing agent to form the
R,S-HMA compound.
In the above formulae, R l is an amino acid side chain.
More particularly, in the above formulae, R1 is a side chain
from any of the naturally occurring amino acids or amino
acid mimetics. In a preferred embodiment, R l is a benzyl
group, a substituted benzyl group, an S-phenyl group, an
alkyl group or a para-nitrobenzene group. In an even more
preferred embodiment, Rl is a benzyl group. R2 , in the
above formulae, is a blocking or protecting group. It will be
readily apparent to those of skill in the art that suitable-
amino blocking groups include, for example, those known to
be useful in the art of stepwise synthesis of peptides.
Included are acyl type protecting groups (e.g., formyl,
trifiuoroacetyl, acetyl, etc.), aromatic urethane type protect-
ing groups (e.g., benzyloxycarboyl (Cbz), substituted Cbz,
25 etc.), aliphatic urethane type protecting groups (e.g.,
t-butyloxycarbonyl (Boc), isopropylcarbonyl,
cyclohexyloxycarbonyl, etc.) and alkyl type protecting
groups (e.g., benzyl, triphenylmethyl, etc.). In a presently
30 preferred embodiment, the blocking group is selected from
the group consisting of Boc, Cbz and Moc
(methoxycarbonyl). In the above fomulae, Xl is a leaving
group. Suitable leaving groups will be readily apparent to
those of skill in the art. In a presently preferred embodiment,
35 the leaving group is a halo group (e.g., CI, Br, F or I). In an
even more preferred embodiment, Xl is a chloro or bromo
group. Although many of the compounds disclosed herein
contain the exemplar designation "halo," such as halomethyl
40 ketone (HMK) or halomethyl alcohol (HMA), it will be
readily apparent to those of skill in the art that other leaving
groups can be used in place of the halo group.
In the above embodiment, the reduction is carried out
using a non-chelating, bulky reducing agent. It has surpris-
45 ingly been discovered that non-chelating, bulky reducing
agents favor the S,R-diastereomer. Examples of non-
chelating, bulky reducing agents suitable for use in the
methods of the present invention include, but are not limited
50 to, lithium aluminum t-butoxyhydride (LATEH), sodium
tris-t-butoxyborohydride (STBH). In a presently preferred
embodiment, the non-chelating, bulky reducing agent is
LATBH. Once formed, the R,S-HMAcan be reacted with an
alkali metal base to form an R,S-epoxide. An exemplar
55 embodiment of the above method is illustrated by the
following reaction scheme:
Synthesis of R,S-Boc-Epoxide by LA TBH Reduction
TABLE 1
HMK Reductions:
Reagent(s) Solvent(s) Temp Time R,S:S,S
Li(OtBu)3AIH Et20 OC 3 Hrs 8:1
(+)-Dip Chloride TM(l.4 eq) THF 5C-RT 12 Hrs 5:1
K-Selectride ® THF Reflux 2 Hrs 2:1
K-Selectride ®rn(OiPr)4 THF 25 C 30 Min 2:1
KS-Selectride ® THF RT 2 Hrs 2:1
K-Select./MgBr2*OEt2 THF RT 30 Min 2.6:1
R-Alpine Borane(Conc.) THF Reflux 9 Dys 1:1
L-Selectride ® THF RT. 1 Hr 0.9:1
NaBH4/CeCI3(anh.) THF RT 2 Hrs 0.8:1
N-Selectride ® EtOHjTHF RT. 2 Hrs 0.7:1
NaBH4/CeCI3*7H20 THF 25 C 18 Hrs 0.7:1
NaBH4/EDTA(Na2*2H20) THF RT 30 Min 0.7:1
NaCNBH3 THF RT 36 Hrs 0.7:1
(+)-2-ButanoliNaBH4 THF RT 1 Hr 0.6:1
Cp2TiBH4 Glyme RT. 30 Min 0.6:1
NaBH4 THF 25 C 2 Hrs 0.6:1
NaBH4/(-)-2-Butanol THF RT 30 Min 0.6:1
NaBH4/AI(OiPr)4 THF Reflux 2 Hrs 0.6:1
NaBH4/DiacetoneDglucose THF RT 12 Hrs 0.6:1
NaBH4/EDTA THF RT 12 Hrs 0.6:1
NaBH4/L-Tartaric Acid THF 5C 1 Hr 0.6:1
NaBH/MgBr2*OEt2 THF RT 1 Hr 0.6:1
BH3-t-butylamine THF RT. 1 Hr 0.5:1
LAH THF 25 C 1 Hr 0.5:1
LS-Selectride ® THF RT 1 Hr 0.5:1
NaBH4/D-Tartaric Acid THF RT 30 Min 0.5:1
(+)-2-Butanol * BH3 THF RT 1 Hr 0.4:1
NaBH4/CaCI2 MeOH RT. 1 Hr 0.4:1
AminoAlcohol Borane THF 25 C 12 Hrs 0.3:1
Na(PEG)2BH2 THF RT 30 Min 0.3:1
THF*BH3 EtOHjTHF RT. 2 Hrs 0.2:1
AI(iOPr)3 IPA SOC 3 Dys 0.05:1
Na HB(OCH3)3 MeOH RT 1 Hr 1:1
the method comprising: reducing a compound having the
following general formula:
As such, in one embodiment, the present invention pro-
vides a method for preparing an R,S-halomethyl alcohol
(R,S-HMA) compound having the following general for-
mula:
R,S-HMAS,S-HMAis <1:1. Other reducing agents, such as
LiAlH4, sodium cyanoborohydride, potassium borohydride,
etc., under a variety of reaction conditions, also fail to
provide >1:1 R,S-HMAS,S-HMA. In fact, a perusal of the
literature supports theobservation that S,S-HMA is the pre- 5
ferred isomer using coordinating reducing reagents, such as
borohydrides or aluminium hydrides (see, U.S. Pat. Nos.
5,684,176 and 5,847,144, both of which issued to Hilpert).
In contrast to the teachings of both the scientific and
patent literature, it has now been discovered that the reduc- 10
tion of HMK proceeds with high R,S diastereoselectivity
when lithium aluminum t-butoxyhydride (LATBH) is used
as the reducing agent. Quite surprisingly and in contrast to
the findings of the prior art, it has been found that the
reduction of HMK with LATBH in, for example, diethyl-
ether provides a 8:1 mixture ofR,S-HMAS,S-HMAin 97% 15
yield. This high diastereofacial selectivity of the LATBH
reducing agent is unusual since reduction of HMK with
similar reducing agents, such as lithium aluminum hydride
or sodium borohydride, do not favor R,S diastereoselectivity
(see, U.S. Pat. Nos. 5,684,176 and 5,847,144, both of which 20
issued to Hilpert).
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-continued
5
with a reducing agent selected from the group consisting
of sodium cyanoborohydride, cerium chloride/sodium
borohydride, K-Selectride®, KS-Selectride® and (+)-
Dip Chloride™ to form the R,S-HMA compound. In
this method, Rl is an amino acid side chain; R2 is a
blocking group; and Xl is a leaving group. It will be
readily apparent to those of skill in the art that the
foregoing discussions relating to R1 , R2 and Xl and
their preferred embodiments are fully applicable to this
method and, thus, will not be repeated.
As with the previously described method, the reduction is
preferably carried out in a solvent. It will be readily apparent
to those of skill in the art that numerous solvents can be
20 used. Exemplar solvents include, but are not limited, to the
following: diethyl ether, THF, MTBE and mixtures thereof.
In a preferred embodiment, diethyl ether or THF is
employed as the solvent. Moreover, as with the previously
described method, the reduction can be carried out at a
25 temperature ranging from about _30° C. to about 25° C. In
a presently preferred embodiment, the reduction is carried
out at a temperature ranging from about _5° C. to about 5°
C.
In yet another embodiment, the present invention pro-
30 vides a method for isolating an R,S-halomethyl alcohol
(R,S-HMA) from a mixture of R,S-HMA and S,S-HMA.
S,S-HMA is crystalline and is relatively easy to purify. In
contrast, the R,S-HMA is soluble in most organic solvents
and is difficult to purify by standard purification techniques,
35 such as recrystallization. Mixtures of R,S-HMA and S,S-
HMA can be separated by column chromatography or by
preparative scale HPLC, but are not practical economically.
It has now been discovered that a mixture of R,S-HMA
and S,S-HMA can be separated on the basis of differential
40 solubility; R,S-HMA is soluble in hot hexanes, whereas the
crystalline diastereomer, S,S-HMA, is not. As such, the
present invention provides a method for isolating an R,S-
halomethyl alcohol (R,S-HMA) from a mixture of R,S-
HMA and S,S-HMA, the method comprising: combining the
45 mixture of R,S- and S,S-HMAs with hexane and heating to
a temperature ranging from 50° C. to about 60° C. to
produce a hexane extractant; cooling the hexane extractant
to a temperature ranging from about 0° C. to about 10° c.,
filtering the hexane extractant to form a first retentate and
50 recovering the first retentate; combining the first retentate
with hexane to form a hexane solution, heating the hexane
solution to a temperature ranging from about 50° C. to about
60° c., and cooling the hexane solution to a temperature
ranging from about 30° C. to about 40° C. to produce a
55 suspension; and filtering the suspension to form a second
retentate and recovering the second retentate, wherein the
R,S-HMA is present in the second retentate.
For instance, a crude reaction mixture, consisting of
50-90% R,S-HMA, 10-50% S,S-HMA and 0-10%
60 Me-ester, was extracted with hot hexane and the resulting
hexane extractant was cooled to 10° C. and filtered to
provide about 94% pure R,S-HMA in 74% yield (based on
HMK); the major contaminant was S,S-HMA (5%).
Attempts to purify the 94% pure material by differential
solubility (above treatment) or by recrystallization from a
variety of solvent/solvent mixtures were not completely
successful. However, it has been determined that the best
10
H
Cl
the method compnsmg: reducing a halomethyl ketone 65
(HMK) compound having the following general for-
mula:
In this embodiment, the reduction is preferably carried out
in a solvent. It will be readily apparent to those of skill in the
art that numerous solvents can be used. Exemplar solvents
include, but are not limited, to the following: diethyl ether,
tetrahydrofuran (THF) and methyl t-butyl ether (MTBE) and 15
mixtures thereof. Quite surprisingly, it has been found that
the reduction of LATBH is dependent on the solvent
employed. For instance, when diethyl ether is used as the
solvent, a 8:1 mixture of R,S-HMAS,S-HMA is obtained.
However, when THF or MTBE is used as the solvent the
ratio of R,S-HMAS,S-HMA is less than or equal to about
2:1. Based on these result, it is thought that a variety of
factors, such as steric, solvation and chelation, are respon-
sible for the high R,S diastereoselectivity observed in
LATBH reduction of HMK. Thus, when LATBH is used as
the reducing agent, diethyl ether is preferably used as the
solvent.
LATBH is commercially available as a white powder and
is used as a suspension in diethyl ether. Alternately, LATEH
can be prepared in situ by the reaction of LAH with 3
equivalents of t-butylalcohol in diethylether and then reacted
with HMK. The best solvent, as judged on basis of R,S-
diastereoselectivity, is diethyl ether. However, the solubility
of HMK in diethyl ether is relatively low and a large amount
of diethyl ether is needed to dissolve CMK, thereby reducing
reactor efficiency to some extent. The reactor efficiency can
be improved by either adding HMK as a solid or,
alternatively, as a solution in a secondary solvent (e.g., THF,
toluene, ethyl acetate, etc.) to a suspension of LATBH in
diethyl ether. The reaction rate is not affected, but the
diastereoselectivity can be reduced from 8: 1 in pure diethyl
ether to about 5:1 with the above modifications.
In this embodiment, the reduction can be carried out at a
temperature ranging from about _30° C. to about 25° C. In
a presently preferred embodiment, the reduction is carried
out at a temperature ranging from about _5° C. to about 5°
C. At lower temperatures, larger amounts of solvent are
needed to maintain homogeneity; whereas at high
temperatures, formation of the epoxide, resulting from
intramolecular cyclization, is observed. At 0° c., the reduc-
tion reaction is rapid and is complete in less than about 30
minutes. It will be readily apparent to those of skill in the art
that the progress of the reduction reaction can be monitored
by, for example, HPLC, and the reaction is deemed complete
when the amount of unreacted HMK is less than about 1%.
In another embodiment, the present invention provides a
method for preparing an R,S-halomethyl alcohol (R,S-
HMA) compound having the following general formula:
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way to purify the 94% pure R,S-HMAis to dissolve it in hot
hexane (about 60° C.), cool to about 40° c., and then
allowing the mixture to crystallize at about 35° C. to about
37° C. for at least 2 h. The crystallized product is then
filtered at about 30° C. to about 35° C. to provide about 5
99.5% pure R,S-HMA in 83% recovery. Interestingly, it has
been found that if the mixture is cooled to 25° C. and
filtered, a mixture consisting of about 94.5% R,S-HMA and
5.5% S,S-HMA, is obtained. This result is surprising
because S,S-HMA is more crystalline and is not soluble in 10
hexane, thus suggesting that S,S-HMA, not R,S-HMA,
should be the first to crystallize. Although a variety of
solvent/solvent mixtures, such as methanol, methanol/water,
toluene, dibutyl ether, etc., have been used to purify 94%
pure R,S-HMA, the highest degree of purity/recovery is 15
obtained with the hot hexane method of the present inven-
tion.
Once prepared and purified, the R,S-HMA can be con-
verted into an R,S-epoxide. As such, in another embodiment,
the present invention provides a A method for preparing an 20
R,S-epoxide compound having the following general for-
mula:
12
particularly, in one embodiment of the inversion method, the
present invention provides a method for preparing an R,S-
epoxide having the following general formula:
the method comprising: (a) reducing a haloketone (HMK)
compound having the following general formula:
(I)
with a reducing agent to form an S,S-haloalcohol (S,S-
HMA) compound having the following general for-
mula:
25
(II)
OH
H~. 1 _1.R1y ~x,
R2HN
the method comprising: reducing a haloketone (HMK) 30
compound having the following general formula:
(I)
35
(b) contacting the S,S-HMA compound of Formula II
with a member selected from the group consisting of
arylsulfonyl halides and alkylsulfonyl halides in the
presence of an amine to form an S,S-halomethyl sul-
fonyl (S,S-HMS) compound having the following gen-
eral formula:
with a non-coordinating reducing agent to form an R,S- 40
haloalcohol (R,S-HMA) compound having the follow-
ing general formula:
(II)
(III)
45
and contacting the R,S-HMA compof Formula II with an 50
alkali metal base to form the R,S-epoxide compound. It
will be readily apparent to those of skill in the art that
the foregoing discussions relating to Rl , R2 and Xl and
their preferred embodiments are fully applicable to this
method and, thus, will not be repeated. In a presently 55
preferred embodiment, the non-coordination reducing
agent is LATBH and the reduction is carried out in
diethyl ether. In another presently preferred
embodiment, the alkali metal base is selected from the
group consisting of NaOH, KOH, LiOH, NaOCH3 , 60
NaOCH2 CH3 and KOtEu. In a further preferred
embodiment, KOH is the alkali metal base used. In
another embodiment, calcium hydroxide can be used.
B. THE INVERSION METHOD
65
In one embodiment of the inversion method, R,S-epoxide
is prepared by a four step process illustrated below. More
(c) contacting the S,S-HMS compound of Formula III
with an acetate in the presence of a phase transfer
catalyst and water to form an R,S-halomethyl acetate
(R,S-HMAc) compound having the following general
formula:
(IV)
and (d) contacting the R,S-HMAc compound of Formula
IV with an alkali metal base to form the R,S-epoxide.
It will be readily apparent to those of skill in the art that
the foregoing discussions relating to R1 , R2 and Xl and
their preferred embodiments are fully applicable to this
method and, thus, will not be repeated. In the above
formulae, R3 is a functional group including, but not
limited to, arylsulfonyls and alkylsulfonyls. In a pres-
ently preferred embodiment, R3 is a member selected
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In the third step, i.e., step (c), the S,S-HMS is reacted with
an acetate in the presence of a phase transfer catalyst and
water to from a HMAc. Suitable acetates for use in the
present method include, but are not limited to, the following:
5 cesium acetate, potassium acetate, tetrabutylammonium
acetate and sodium acetate. In a presently preferred
embodiment, the acetate is cesium acetate. A variety of
phase transfer catalysts (PTCs) can be used in carrying out
step (c). Exemplar phase transfer catalysts include, but are
10 not limited to, crown ethers (e.g., 18-crown-6, dibenzo
crown ether, etc.), quaternary ammonium salts and quater-
nary phosphonium salts (e.g., tetrabutylammonium bromide
(TATE), aliq. 336, etc.). In a presently preferred
embodiment, the phase transfer catalyst is a crown ether. The
15 crown ether 18-crown-6 is particularly preferred because it
allows for the production of R,S-HMAc with least amount
of side product. Moreover, the rate of reaction with
18-crown-6 is much faster than with any of the other phase
transfer catalysts. In addition, 18-crown-6 can be easily
20 removed from the product by a simple water wash.
Step (c), i.e., the displacement reaction, can be carried out
in a variety of different solvents. Suitable solvents include,
but are not limited to, hydrocarbons (e.g., hexane, heptane,
etc.), aromatic hydrocarbons (e.g., toluene, xylene, benzene,
25 etc.) and chlorinated solvents (e.g., CCI4 , dichloroethane,
chlorotoluenes, etc.). In a presently preferred embodiment,
toluene is used as the solvent because it can be used for both
steps (b) and (c), and it can be used as a crystallization
solvent for the R,S-HMAc. In addition, toluene is commer-
30 cially available from a variety of sources and can be recycled
in high efficiency. The displacement reaction, i.e., step (c)
can be carried out at a temperature ranging from about 20°
C. to about 100° C. In a presently preferred embodiment, the
displacement reaction is carried out at a temperature ranging
35 from about 20° C. to about 100° C.
In addition to the foregoing, it has been found that the
displacement reaction is dependent on the amount of water
present in the reaction mixture. Presumably, a small amount
of water is needed to overcome the lattice energy of the
40 metal acetate, thereby making the nucleophile accessible for
the displacement reaction. However, it has been found that
increased amounts of water will reduce the reactivity of the
nucleophile by solvating it. Thus, in a preferred
embodiment, the water is maintained between about 0.5%
45 and about 10.0% and, more preferably, between about 0.5%
and about 5%. Once the displacement reaction is completed,
the crude product can be isolated by crystallization from, for
example, toluene/heptane to give typically greater than
99.5% pure R,S-HMAc in high yield. Alternately, the R,S-
50 HMAc can be isolated and then recrystallized from, for
example, methanol/water to give pure R,S-HMAc.
In the final step of the above method, i.e., step (d), the
R,S-HMAc is reacted with an alkali metal base to form the
R,S-epoxide. It has been found that hydrolysis of the R,S-
55 HMAc followed by subsequent intramolecular ring closure
provides the R,S-epoxide in near quantitative yield. In a
presently preferred embodiment, the alkali metal base is
selected from the group consisting of NaOH, KOH, LiOH,
NaOCH3 , NaOCH2 CH3 and KOtEu. In another preferred
60 embodiment, step (d) is carried out is a solvent. Suitable
solvents include, but are not limited to, hydrocarbons, aro-
matic hydrocarbons, chlorinated solvents and ethers (e.g.,
THF). In a presently preferred embodiment, the solvent is a
mixture of toluene and THE
In a particularly preferred embodiment of step (d), the
R,S-HMAc is reacted with aqueous potassium hydroxide
(KOH) in a mixture of THF and ethanol. Evaporation of
from the group consisting of a methylsulfonyl group
(i.e., a mesyl group), a toluenesulfonyl group (i.e., a
tosyl group), a trifiuoromethanesulfonyl group (i.e., a
trifiate group) and a para-nitrobenzene sulfonyl group
(i.e., a nosyl group). It will be readily apparent to those
of skill in the art that other leaving groups can be used
as R3 in place of the arylsulfonyl and alkylsulfonyl
groups. R4 , in the above formulae, is an acyl group
derived from the acetate. In a presently preferred
embodiment, R4 is an acetyl group.
In the first step, i.e., step (a), a HMK is reduced with a
reducing agent to form an S,S-HMA. In a preferred
embodiment, the reducing agent is selected from the group
consisting of sodium borohydride, lithium aluminum
hydride and sodium cyanoborohydride. In another preferred
embodiment, step (a) is carried out in a solvent. Suitable
solvents include, but are not limited to, ethanol, methanol,
isopropanol, THF, diethyl ether, etc. The reduction can be
carried out at a temperature ranging from about _30° C. to
about room temperature and, more preferably, at about _20°
C. In a presently preferred embodiment, the reduction step
is carried out using sodium borohydride in ethanol to
provide a 6:1 mixture of S,S-HMAR,S-HMAin 98% yield.
The S,S-isomer is highly crystalline and can be easily
purified by recrystallization to provide >99.8% pure S,S-
HMA in 80% yield.
In addition to the foregoing, HMAcan also be prepared by
Merwin Pondroff Verley reduction of HMK. In this process,
HMK is reacted with aluminum isopropoxide in refiuxing
isopropyl alcohol (IPA) to give S,S-CMA in high diastereo-
selectivity. Presumably, under these conditions, the reduc-
tion occurs under chelation control and a mixture of S,S-
HMAR,S-HMA with ratios as high as 20: 1 is obtained (see,
U.S. Pat. Nos. 5,684,176 and 5,847,144, both of which
issued to Hilpert).
In the second step, i.e., step (b), an S,S-HMA is reacted
with an arylsulfonyl halide or an alkylsulfonyl halide in the
presence of an amine to form an S,S-halomethyl sulfonyl
(S,S-HMS). Suitable amines include, but are not limited to,
trialkylamines (e.g., trimethylamine, triethylamine, etc.),
pyridine, 4-dimethylamino pyridine, etc. In a presently
preferred embodiment, the amine is triethylamine. Step (b)
can be carried out in a variety of different solvents. Exemplar
solvents include, but are not limited to, the following:
chlorinated solvents (e.g., methylene chloride,
dichloroethane, chlorotoluene, etc.), aromatic hydrocarbons
(e.g., toluene, xylenes, etc.), ethyl acetate, ethers (e.g., THF,
diethyl ether, etc.), etc. In another presently preferred
embodiment, step (b) is carried out at a temperature ranging
from about _30° C. to about 100° C. and, more preferably,
from about 10° C. to about 70° C.
In a particularly preferred embodiment of step (b), the
S,S-HMA is reacted with methanesulfonyl chloride in tolu-
ene in the presence of an equivalent amount of triethylamine
to give the corresponding 2S,3S-CMA Mesylate in 98%
yield. The reaction is exothermic and is best conducted at a
temperature ranging from about from about 10° C. to about
70° C. The crude mesylate is recrystallized from toluene to
provide greater than 95% pure S,S-CMA Mesylate in near
quantitative yield. However, in the preferred process, S,S-
CMA Mesylate is not isolated and the solution of crude
S,S-CMA mesylate in toluene is used, without purification,
in the next step, i.e., step (c). Although this mesylation step
can be conducted in a variety of solvents, toluene is the
preferred solvent because it can be used in the next step, 65
thereby eliminating a solvent exchange step from the pro-
cess.
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the method comprising: (a) contacting an S,S-halomethyl
sulfonyl (S,S-HMS) compound having the following
general formula:
with a carbamate forming acetate to form a cyclic car-
bamate having the following general formula:
60
and (b) contacting the cyclic carbamate with an alkali
metal base to form the R,S-epoxide. It will be readily
apparent to those of skill in the art that the foregoing
discussions relating to R\ R2 , R3 and Xl and their
preferred embodiments are fully applicable to this
method and, thus, will not be repeated. A "carbamate-
forming acetate," as used herein, refers to an acetate
that contains a sufficient leaving group. Exemplar
carbamate-forming acetates include, but are not limited
to, sodium trichloroacetate, potassium trichloroacetate,
tetrabutylammonium trichloroacetate, sodium
tribromoacetate, potassium tribromoacetate sodium tri-
fiuoroacetate and potassium trifiuoroacetate.
35 As with the previously described methods, step (a) can be
carried out in a variety of solvents, such as hydrocarbons
(e.g., hexane, heptane, etc.), aromatic hydrocarbons (e.g.,
toluene, xylene, benzene, etc.) and chlorinated solvents
(e.g., CCI4 , dichloroethane, chlorotoluenes, etc.). In a pre-
ferred embodiment, the solvent is toluene. In step (b) of the
40 above method, the cyclic carbamate is reacted with an alkali
metal base to form the R,S-epoxide. In a presently preferred
embodiment, the alkali metal base is selected from the group
consisting of NaOH, KOH, LiOH, NaOCH3 , NaOCH2 CH3
and KOtEu. In another preferred embodiment, step (b) is
45 carried out in a solvent. Suitable solvents include, but are not
limited to, hydrocarbons, aromatic hydrocarbons, chlori-
nated solvents and ethers (e.g., THF). In a presently pre-
ferred embodiment, the solvent is a mixture of THF and
ethanol.
In connection with the above method, the present inven-
tion provides a cyclic carbamate compound having the
following general formula:
55
50
Epoxide
NaOH
-Cl
NHtBOC
15
MsCl
Cl Et;N
Preparation of the R,S-Epoxide Using One
Embodiment of the Inversion Method
NHtBOC
In another embodiment of the inversion method, the
present invention provides a method for preparing an R,S-
epoxide compound having the following general formula:
NHtBOC
solvent followed by tituration of the crude product with
hexane afforded the desired R,S-epoxide as a low melting,
white solid.
Since the R,S-epoxide is soluble in most solvents, it is
difficult to purify. In addition, the R,S-epoxide is reactive 5
towards ring opening reactions and will react with potassium
hydroxide in ethanol to give the corresponding glycol or the
ethoxyglcyol side products. Using this method of the present
invention, high purity R,S-epoxide (»99.5%) has been
prepared by incorporating the purity at the R,S-HMAc stage 10
and then maintaining the purity by minimizing side reactions
in the final step. Thus, it is important that the above
conversion is achieved in near quantitative yield and without
formation of side products. Again, in a preferred embodi-
ment of this method, this is accomplished by employing 15
aqueous KOH. Presumably, in this form, the hydroxide is
nucleophilic enough to allow hydrolysis to occur, but is not
nucleophilic enough to react with the R,S-epoxide and form
side products.
Using this method of the present invention, greater than 20
99.5% pure R,S-epoxide can be prepared in 95-97% yields.
The R,S-epoxide prepared by this process can be character-
ized by NMR, HPLC, TLC and differential scanning calo-
rimetry (DSC). Moreover, despite difficulties encountered in
the prior art relating to the purification of the R,S-epoxide, 25
it has now been discovered that the R,S-epoxide can be
purified by recrystallization from petroleum ether. This is an
important discovery because traditional purification
techniques, such as chromatography, are not applicable due
to instability of the R,S-epoxide towards silica gel and 30
alumina. As such, in a preferred embodiment, the above
method further comprises: purifying the R,S-epoxide by
recrystallization with petroleum ether. An exemplar embodi-
ment of the above method is illustrated by the following
reaction scheme:
In the above formula, R l is an amino acid side chain (e.g.,
benzyl); R2 is hydrogen or a blocking/protecting group (e.g.,
butyloxycarbonyl (Eoc), methoxycarbonyl (Moe), benzy-
65 loxycarboyl (Cbz), etc.); and Xl is a leaving group (e.g., a
The bromomethylalcohol was dehalohydroxylated to give
the olefin (i.e., the compound of Formula V) by zinc metal
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with a hydrohalo acid to form a compound having the
following general formula:
18
15
embodiment, sodium borohydride is the reducing agent
employed in step (b). Finally, in step (c), compound III is
dehalohydroxylated to form the desired alkene. Suitable
dehalohydroxylating compounds include, but are not limited
5 to, zinc (0) metals (e.g., zinc dust), nickel metals, zinc
mercury amalgan, etc. Step (c) can be carried out in a
number of different solvents. Suitable solvents include, but
are not limited to, methanol, ethanol, isopropanol, THF,
10 MTBE, toluene, etc. In a presently preferred embodiment,
zinc dust in ethanol is used in step (c).
Once prepared, the alkene can be converted to the R,S-
epoxide using, for example, m-chloroperbenzoic acid as
illustrated below.
In one particularly preferred embodiment of this method,
reaction of the diazoketone (i.e., the compound of Formula
I), which is prepared from phenylalanine using
diazomethane, with hydrobromic acid gives the bromoke-
20 tone (i.e., the compound of Formula II) in 77% yield.
Reduction of the bromoketone with sodium borohydride
under conditions similar to those used for the chloroketone
gave high selectivity for the S,S-bromomethylalcohol (i.e.,
the compound of Formula III) over the R,S-diastereomer.
25
The desired S,S-isomer was isolated in 85% yield after
recrystallization (see, Parkes, et aI., J. Org. Chern.,
59:3656-3664 (1994).
The bromomethylalcohol was dehalohydroxylated to give
30 the olefin (i.e., the compound of Formula V) by zinc metal
in ethanol. Upon work up, the t-BOC protected S-3-amino-
4-phenyl-1-butene was isolated in 77% yield. Using this
method of the present invention, very pure material was
35 prepared without the problems of racemization associated
with the reaction of the t-BOC protected S-phenylalanal
route. The alkene was converted to the R,S-epoxide using,
for example, a published route using m-chloroperbenzoic
acid. An exemplar embodiment of the above method is
40 illustrated by the following reaction scheme:
(I)
(II)
(IV)
the method comprising: (a) contacting a compound hav-
ing the following general formula:
17
in ethanol. Upon work up, the tert-butyloxycarbonyl
(t-BOC) protected S-3-amino-4-phenyl-1-butene was iso-
lated in 77% yield. Using this method of the present
invention, very pure material was prepared without the
problems of racemization associated with the reaction of the
t-BOC protected S-phenylalanal route. The alkene was con-
verted to the R,S-epoxide using, for example, a published
route using m-chloroperbenzoic acid. An exemplar embodi-
ment of the above method is illustrated by the following
reaction scheme:
In another embodiment, the present invention provides a
method for preparing an alkene having the following general
formula:
(b) reducing a compound of Formula II with a reducing
agent to form a compound having the following general 45
formula: Preparation of the R,S-Expoxide Using the Alkene
Method
(III)
OH
H
H
R~X'
_i '
R2HN
and (c) dehalohydroxylating a compound of Formula III 55
to form the alkene. It will be readily apparent to those
of skill in the art that the foregoing discussions relating
to R\ R2 , and Xl and their preferred embodiments are
fully applicable to this method and, thus, will not be
repeated. 60
In step (a), a compound of Formula I is reacted with a
hydrohalo acid to form a compound of Formula II. Suitable
hydrohalo acids include, but are not limited to, hydrobromic
acid, hydrochloric acid and hydroiodic acid. In a presently
preferred embodiment, the hydrohalo acid is hydrobromic 65
acid or hydrochloric acid. Step (b) can be carried out using
any of a variety of reducing agents. In a presently preferred
NHtBOC
NHtBOC
BrMA
HBr
-
Zn
-Br EtOH
NHtBOC
BMK
NHtBOC
Br
[H]
-
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-continued
NHtBOC
BOC-E
20
1 h. The mixture was extracted with ethyl acetate (500 mL)
and then concentrated on a rotary evaporator to a volume of
ca. 300 mL. Water (100 mL) and the remaining ethyl acetate
was removed under reduced pressure at 45° C. The precipi-
5 tated product was filtered, washed with water (200 mL), and
dried in a vacuum oven at 45° C./28 inch-Hg for 15 h to give
23.8 g (95% yield) of a white solid. HPLC analysis revealed
that the solid contained a mixture of 41% R,S-CMA and
59% S,S-CMA.
10
3. Preparation of R,S-CMA by Reduction with
Cerium Chloride/sodium Borohydride
4. Preparation of R,S-CMA4 by Reduction with
LATBH
Lithium tri-t-butoxyaluminohydride (LATBH) (93.87 g,
0.369 mol, 1.1 eq) and anhydrous diethyl ether (500 mL)
were placed in a reactor and cooled to 2° C. A solution of
CMK (99.84 g, 0.355 mol) and anhydrous diethyl ether
(2000 mL) was added over 90 min maintaining an internal
temperature of less than 5° C. After the addition was
complete, the mixture was stirred for 30 min at which point
HPLC analysis indicated no starting material remaining. The
reaction was slowly quenched water (1500 mL) and then
acetified with glacial acetic acid (1000 mL) at a rate such the
temperature was below 10° C. The reaction was warmed to
ambient and the organic phase was separated, washed with
water and was evaporated in vacuo to give an orange oil
(100.12 g). Hexanes (500 mL) was added to the flask and
evaporated on the rotary evaporator to remove residual
t-butanol and isobutanol; the evaporation yielded an orange
60 oil/solid (97.34 g, 97% yield).
HPLC and 1 H NMR analysis indicated an approximately
6.5:1 ratio of R,S:S,S CMA. The R,S-isomers was purified
by extraction into refluxing hexanes (300 mL), filtration
while hot to remove the less soluble S,S-isomer, and slow
65 cooling overnight. After filtration and drying, 74.5 g (82.3%
yield) of a product that was 92.1% R,S CMA and 5.4% S,S
CMA by HPLC and 1 H NMR analysis.
A 5000 mL, 3-necked round bottom flask was fitted with
mechanical stirring, Claisen head adapter, condenser, dry
nitrogen inlet, glass enclosed thermocouple temperature
probe, and solids addition funnel, all oven dried at 120° C.
and cooled under dry nitrogen. To a stirred slurry of CMK
(200 g, 0.672 mol, 1.0 eq), cerium chloride heptahydrate
20 (250 g, 0.672 mol, 1.0 eq), and THF (716 g) was added
sodium borohydride (25.5 g, 0.673 mol, 1.0 eq) portionwise
over 70 minutes during which time a 4.5° C. exotherm was
observed. The reaction mixture was stirred for an additional
5 hours at room temperature, at which time HPLC analysis
25 indicated that starting material had been consumed. The
reaction was cooled to 2° C. and ethyl acetate (500 mL) was
added. The reaction was quenched with water (1000 mL) at
a rate to control the production of hydrogen gas and maintain
at a temperature of less than 20° C. The pH of the reaction
30 was adjusted to approximately 6 with glacial acetic acid (18
mL) and additional ethyl acetate (2500 mL) was added to
dissolve the solids. The reaction was warmed to room
temperature and transferred to a 6000 mL separatory funnel.
The organic phase was separated, washed with water and
35 evaporated in vacuo to give 175 g (96% yield) of a white
solid. HPLC analysis of the solid indicated 36% R,S boc-
phenylalanine chloromethylalcohol (CMA) and 60% S,S
CMA; lH NMR analysis confirmed a 0.6:1 R,S:S,S CMA
ratio.
EXAMPLES
1. Preparation of S,S-CMA by Reduction
A. Example I
This example illustrates the preparation of S,S-CMA and
R,S-CMA using the reduction methods of the present inven-
tion.
2. Sodium Cyanoborohydride Reduction of CMK
To a solution of sodium cyanaoborohydride (5.28 g, 84.0
mmol, 1.0 eq) in THF (25 mL) was added a solution of CMK
(25.0 g, 84.0 mmol) in THF (100 mL), followed by addition
of AcOH (10 mL) over 0.5 h at RT. During this addition,
internal temperature was never allowed to rise above 42° C.
After 1.5 h, TLC analysis of an aliquot indicated total
consumption of CMK signaling reaction completion. The
reaction mixture was quenched with H2 0 (250 mL) and the
resulting white slurry was stirred at ambient temperature for
The invention will be described in greater detail by way
of specific examples. The following examples are offered for
illustrative purposes, and are not intended to limit the 15
invention in any manner. Those of skill in the art will readily
recognize a variety of noncritical parameters that can be
changed or modified to yield essentially the same results.
A 500 mL , 3-necked round bottom flask was fitted with
a condenser, thermocouple temperature probe, dry nitrogen
inlet, and magnetic stirring. A stirred solution of chlorom-
ethylketone (CMK) (19.22 g, 0.0645 mol) and Isopropanol
(200 mL) was heated to 50° C. and aluminum isopropoxide
(6.87 g, 0.0337 mol, 1.5 eq) was charged to the reactor. The
reaction mixture was heated at 50° C. for three hours at
which point HPLC analysis indicated 0.4% CMK remained.
After heating for 1 additional hour and cooling to room
temperature, the reaction was quenched with water (200 mL)
and glacial acetic acid (-50 mL) to adjust the pH to 4. The
reaction was transferred to a separatory funnel and the 40
organic solids were extracted into ethyl acetate, resulting in
two clear phases. The phases were split and the organic
phase was evaporated to 18.63 g (97% yield) off-white solid.
S,S-Chloromethylalcohol (S,S-CMA): lH NMR (CDCI3 ): /)
1.37 (s, 9H), 2.97 (m, 2H, 1=5.1 Hz), 3.20 (br d, lH), 45
3.55-3.69 (m, 2H), 3.83-3.93 (m, 2H), 4.59 (br d, lH, 1=6.6
Hz), 7.21-7.34 (m, 5H); HPLC (Short) tR 3.84 min=99.51 %,
4.66 min=0.49%; HPLC (long) tR 13.26 min=99.50%, 17.42
min=0.50%.
Proton NMR analysis of final product indicated -37:1 50
ratio of S,S:R,S Boc-phenylalanine Chloromethylalcohol
(CMA), and traces of acetic acid. HPLC analysis indicated
32:1 ratio of S,S:R,S CMA (95.1% S,S CMA, 3.0% R,S
CMA, 0.6% CMK, and 1.3% impurities from the starting
material e.g. methyl ester, boc-phenylalanine). Further puri- 55
fication was accomplished by recrystallization from heptane.
21
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b. Step 2: Displacement
A second reactor was charged with cesium acetate (241.7
g, 1.125 mol) and 18-crown-6 (33 g, 0.125 mol) in toluene
(400 mL) and the mixture was heated to 70C. Next, a
solution of S,S-CMA mesylate in toluene was added over 1
h and the resulting mixture was heated at 70° C. for an
additional 9 hrs at which time TLC analysis indicated the
reaction was complete. The reactor was cooled to 35° c.,
and water (1 L) was added. The organic layer was separated
and washed with water and the solvent was evaporated until
the concentration of the product was 20% by weight as
determined by 1 H NMR analysis. Heptane (1350 g) was
added and the mixture heated to 55° C. for 30 min, and
cooled to ambient over 1 h. The mixture was then cooled to
5° c., filtered, and the white solid was dried in vacuo to give
131.5 g (77% yield) of (2R,3S)-N-t-butoxycarbonyl-1-
chloro-2-acetoxy-4-phenylbutanamine, a white solid: mp
105-106° c.; lH NMR (CDCI3): /) 1.39 (s, 9H), 2.13 (s, 3H),
2.75 (br d, 2H, 1=7.5 Hz), 3.56 (br d, 2H, 1=6.3 Hz), 4.24
(ddd, 2H, 1=7.4, 2.2 Hz), 4.52 and 4.67 (both br d, lH total,
1=9.6 Hz), 5.03-5.12 (m, lH, 1=6.2, 2.1 Hz), 7.17-7.33 (m,
5H); TLC (silica gel, 30% EtOAclHexane): RrO.75; HPLC
analysis revealed that the product was 99.7% pure.
c. Step 3: Hydrolysis and Ring Closure
AlL flask fitted with a mechanical stirrer, addition
funnel, temperature probe, and a nitrogen inlet was charged
with R,S-CMA Acetate (34.3 g, 100.4 mmol), THF (156
mL), ethanol (90 mL) and water (30 mL). The mixture was
cooled to 0-3° C. and a 43% aq. KOH solution (13.3 g of
86% potassium hydroxide dissolved in 13.3 mL of water)
was added dropwise to the reaction mixture so as to maintain
an internal temperature of <5° C. The reaction mixture was
stirred at 0-3° C. for 1.5 h and then quenched with 6% aq.
sodium biphosphate solution (250 mL); the reaction tem-
perature was maintained below 10° C. during quench.
Diethyl ether (260 mL) was added and the organic layer was
separated, dried (Na2SO4), filtered, and stripped of solvent
under reduced pressure to give a clear oil. Hexane (130 mL)
was added and the resulting mixture was concentrated on a
40 rotary evaporator till <10% hexane remained and the residue
was seeded with crystals of pure R,S-Epoxide. The mixture
was then stored at room temperature for 16 h and the
precipitated solid was collected by filtration and dried to
provide 25.4 g (96%) of the title compound, a white solid:
mp (DSC): 51.56° c.; lH NMR (CDCI3 ): /) 1.39 (s, 9H),
2.59 (s, lH), 2.70 (dd, lH, 1=3.9 Hz), 2.91 (m, 2H, 1=6.6
Hz), 3.01 (m, lH, 1=3.6 Hz), 4.13 (d, lH, 1=7.8 Hz), 4.49 (d,
1H, 1=7.2 Hz), 7.27 (br m, 5H). The purity, as determined by
HPLC analysis, was 99.5%.
d. Alternate Process for Preparation of 2R,3S-
Chloromethylacetate
A4 Ljacketed reactor equipped with a mechanical stirrer,
reflux condenser, temperature probe, and a nitrogen gas inlet
was charged with S,S-CMA Mesylate (246.5 g, 0.65 mol)
and 18-crown-6 (43.4 g, 0.16 mol), cesium acetate (322.8 g,
1.685.7 mol) and toluene (3.2 L). The resulting mixture was
heated at 72° C. for 11 hours, at which point TLC analysis
(silica gel, 30% EtOAclHexane) indicated the starting mate-
rial had been consumed. The organic phase was separated
and concentrated under reduced pressure to provide a white
solid. The residue was dissolved in ethyl acetate (1.2 L) and
the resulting solution was washed with H2 0 (2x550 mL),
dried (Na2SO4)' filtered, and stripped off solvent under
reduced pressure to provide 216 g (97%) of 92% pure
R,S-CMA Acetate. Recrystallization of the crude product
from 85:15 methanol/water provided 99.7% pure R,S-CMA
Acetate in 57% yield. The mother liquor was concentrated
5. Purification of Mixtures of S,S- and R,S-CMA
CMA (170 g of a mixure of 0.6 to 1 isomers) and hexanes
(800 g) were charged to the flask and heated to reflux for 1
hour. The less soluble isomer mix (90% S,S CMA, 9% R,S
CMA) (99.6 g, 58% yield) was removed by filtration of the 5
hot mixture. The filtrate was evaporated to 75% volume,
cooled and filtered to give the more soluble isomer mix
(94% R,S CMA, 3% S,S CMA) 36.7 g (22% yield) were
removed by cold filtration through a 600 mL coarse, sintered
glass funnel. The residual filtrate was dryed in vacuo to give 10
a yellow oil (18.6 g, 11% yield) containing a mixture of
Isomers.
A mixture of 32 g of the crude solid (93% R,S-CMA and
6% S,S-CMA) from the hot hexane recrystallization and
hexanes (600 mL) was heated to 60° C. The resulting 15
solution was slowly allowed to cool to 53° C. and seeded
with R,S-CMA crystals. Further crystallization was
observed at 37° C. at which point significant amount of
white needles had formed in solution. The internal tempera-
ture was maintained between 35-40° C. for 1.5 h, at which 20
point the mixture was hot filtered to provide 25.7 g (80%
recovery) of R,S-CMA as white needles. HPLC analyses
revealed that R,S-CMA was 99.8% pure and contained ca.
0.2% S,S-CMA. Concentration of hexane filtrate on a rotary
evaporator afforded 6.1 g of a white solid which based on 25
HPLC analysis was found to be consist of 91.9% R,S-CMA
and 6.4% S,S-CMA.
R,S-Chloromethylalcohol (R,S-CAL4): lH NMR
(CDCI3): /) 1.36 (s, 9H), 2.94 (m, 2H, 1=7.3 Hz), 3.54 (d, 2H,
1=4.6 Hz), 3.77 (m, lH, 1=2.1 Hz), 3.94 (m, lH, 1=7.3 Hz), 30
4.99 (d, lH, 1=8.8 Hz), 7.24 (br m, 5H); HPLC (Short) tR
3.87 min=0.21%, 4.69 min=99.79%.
B. Example II
This example illustrates the preparation of R,S,-Epoxide 35
using two different inversion methods. In NMR: Varian 300
MHz; HPLC: Hewlett Packard 1100, column C18 reverse
phase using acetonitrile/water with phosphate buffer; melt-
ing points were measured by DSC
1. Preparation of R,S-Epoxide by the Inversion
Route Via An Acetate
a. Step 1: Mesylation A 3 L jacketed reactor equipped with
a mechanical stirrer, addition funnel, reflux condenser, tem-
perature probe, and a nitrogen gas inlet was charged with
S,S-CMA (150.3 g, 0.501 mol) and toluene (1.5 L). The 45
system was flushed with nitrogen and triethylamine (62 g,
0.613 mol) was added. The resulting mixture was treated,
dropwise, with methanesulfonyl chloride (69 g, 0.595 mol).
The rate of addition of methanesulfonyl chloride was main-
tained so as to control the reaction temperature below 50° C. 50
When the addition was complete, the reaction mixture was
stirred for 1 h, sampled and analyzed by HPLC which
indicated that the reaction was complete. The reaction
mixture was slowly quenched into 10% aqueous potassium
bicarbonate solution, and the organic phase was separated 55
and washed with water. The organic layer containing the
mesylate derivative was then dried azeotropically and used
without isolation in the displacement reaction. In order to
obtain yield/purity data, a sample of reaction mixture was
withdrawn and stripped off solvent under reduced pressure 60
to give S,S-CMA mesylate, a pale yellow solid: mp
117-121° c.; lH NMR (CDCI3): /) 1.35 (s, 9H), 2.79 (br t,
lH, 1=11.1 Hz), 3.04 (dd, lH, 1=14.4,4.8 Hz), 3.17 (s, 3H),
3.73 (m, 2H, 1=4.5 Hz), 4.15 (ddd, lH, 1=5.1, 4.8, 3.6 Hz
4.69 (br d, lH, 1=6.6 Hz), 5.04 (br s, lH), 7.20-7.34 (m, 65
5H); HPLC revealed that the product was 99.7% (area %)
pure.
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C. Example III
2. Preparation of Bromomethylalcohol (BMA)
A mixture of bromomethylketone (20.3 g, 59.3 mmol),
ethyl acetate (160 mL), and ethanol (240 mL) was cooled to
_30° C. and treated, dropwise, with a slurry of sodium
borohydride (1.16 g, 30.7 mmol) in ethanol (80 mL). The
reaction mixture was stirred at _30° C. for 30 min. and
quenched with acetic acid (4 mL); the reaction temperature
was maintained below _20° C. during the quench. The
reaction mixture was then warmed to room temperature and
treated with water (100 mL) and ethyl acetate (150 mL). The
layers were separated and the organic layer was filtered to
give 2.8 g of 96.6% pure S,S-BMA. The organic layer was
then dried (Na2S04), filtered, and evaporated in vacuo to
give 14.2 g of a mixture consisting of 85% S,S-BMA, 6%
R,S-BMA, and 5% methyl ester. lH NMR (S,S-BMA;
CDCI3 ): /) 1.36 (s, 9H), 2.98 (br m, 2H, 1=4.5 Hz), 3.46 (br
m, lH, 1=9 Hz), 3.54 (br m, lH), 3.86 (br s, 2H), 4.56 (br
s, lH), 7.20-7.31 (m, 5H); HPLC (Short) tR 2.29 min=
0.07%, 3.88 min=2.68%, 4.29 min=96.61%, 5.25 min=
0.64%.
3. Preparation of BOC-Alkene
A mixture of crude BMA (12.1 g, 35.2 mmol) prepared
above and ethanol (240 mL) was heated to reflux and zinc
dust (22.4 g, 343 mmol) was added. The resulting mixture
was refluxed for 5 h, at which time TLC analysis (silica gel,
30% EtOAclHexane) indicated the starting material had
been consumed. The reaction mixture was cooled to room
temperature, unreacted zinc dust was removed by filtration,
c. Mechanistic Discussion
Without intending to be bound by any theory, it is thought
that the reaction occurs through the following mechanism.
Attack of a trichloroacetate anion on the secondary mesylate
5 in an SN2 fashion inverts the stereochemistry and provides
the intermediate R,S-chloromethyltrichloroacetate (R,S-
CMAcCI3 ). Due to the excellent leaving group ability
of:CC13 (trichlorocarbene), nucleophilic attack of the car-
bamate nitrogen on the acetate carbonyl and subsequent (or
concurrent) loss of a proton provides the cyclic carbamate.
It is thought that treatment of this species with aqueous base
favors reaction of the hydroxide at the cyclic carbonyl,
possibly due to the added benefit of relieving the ring strain
of the molecule, resulting in the expected epoxide
(55-60%).
This example illustrates the preparation of the R,S-
20 epoxide by the epoxidation of an alkene.
1. Preparation of Bromomethyl Ketone (BMK)
A solution of diazomethyl ketone (DMK) in ethyl acetate/
diethyl ether (16.8 g solution, 1 g DMK, 3.5 mmol) was
25 cooled to 5° C. and treated dropwise with a solution of
hydrobromic acid (1.8 g, 10.6 mmol); the reaction tempera-
ture was maintained below 10° C. during the addition. The
resulting mixture was stirred at 0-5° C. for 2 hours and
quenched with water (20 mL). The organic layer was sepa-
rated and washed with water (3x20 mL) until the pH of the
final water wash was >6. The organic layer was concentrated
on a rotary evaporator to give 0.92 g (77%) of an off-white
solid. The product purity, as determined by HPLC, was 91%.
lH NMR-(S,S-BMK; CDCI3 )): /) 1.41 (s, 9H), 3.07 (m, 2H,
35 1=6.6 Hz), 3.94 (m, 2H, 1=16.2 Hz), 4.72 (q, lH, 1=7.2 Hz),
5.07 (d, lH, 1=7.5 Hz), 7.20-7.31 (br m, 5H).
on rotary evaporator, treated with water, and chilled to 5° C.
to provide an additional 22 g of 98.2% pure product, thus
increasing the total yield of R,S-CMA Acetate to 76%.
2. Preparation of R,S-Epoxide by the Inversion
Route Via Trichloroacetic Acid
a. Step 1: Preparation of 'Cyclic Carbamate'
A 250 mL round-bottom flask equipped with a magnetic
stir bar, reflux condenser, temperature probe, and a nitrogen
gas inlet was charged with 9.98 g (26.4 mmol) of S,S-
chloromethyl mesylates (CMMs), 0.434 g (1.35 mmol) of 10
tetrabutylammonium bromide (TBAB), 7.46 g (40.2 mmol)
of sodium trichloroacetate, and flushed vigorously with N2 .
Toluene (104 mL, 90 g) was added under a steady stream of
N2 and the resulting slurry was heated to _45° C. The
reaction mixture was stirred at 45° C. overnight, at which 15
point TLC analysis (silica gel, 30% EtOAclHexane) indi-
cated the starting material had been consumed. The toluene
phase was transferred from the reaction vessel into a 500 mL
separatory funnel and EtOAcIH20 (50 mL!100 mL), used to
rinse the reactor, was combined with the organic layer. After
separating the two layers, the organic layer was washed with
H2 0 (lx100 mL), dried over Na2S04 , filtered, and removed
under vacuum. The resulting crude solid was dried in a
vacuum oven (45° C.) overnight to provide a yield of 92%
(7.92 g, 24.3 mmol, -90% pure).
This product was combined with the crude cyclic car-
bamate (1.67 g, 5.13 mmol) from a previous small scale
synthesis (CP078-24) and crystallized from MeOHIH2 0 as
follows: 9.59 g of crude product was dissolved in 43 mL (34
g) of MeOH while heating to 45° C. To this warm MeOH 30
solution was slowly added 4 mL of H2 0 and the temperature
allowed to reach ambient without agitation. Needle forma-
tion was rapid and the flask was cooled to 0-5° C. prior to
filtration, yielding 7.24 g (75.5% recovery) of product
(99.42% pure).
b. Step 2: Preparation of R,S-Epoxide
To a 50 mL round-bottom flask equipped with a magnetic
stir bar, temperature probe, and a nitrogen inlet was added a
43% aqueous KOH solution (0.73 g soln., 5.82 mmol) and
1.0 g of H2 0. The contents of the flask were cooled to 0-3° 40
C. with the aid of an ice-bath. A separate flask was charged
with 0.99 g (2.22 mmol) of the 'cyclic carbamate', 3.2 g of
THF, and 1.6 g of EtOH and agitated to dissolve all solids.
The 'cyclic carbamate' solution was added dropwise to the
reaction flask via pipet so as to maintain an internal tem- 45
perature of <4°C. Once addition was complete, the reaction
was stirred at 0-3° C. for -1 hour, at which point the reaction
was quenched by addition of a sodium biphosphate solution
(0.448 g NaH2 P04 , 6.8 g H2 0). The reaction quench was
conducted at such a rate as to keep the internal temperature 50
<10° C. (Note: The reaction was analyzed for completion via
TLC after a 30 min. post-stir and found to contain the
desired epoxide.) The cloudy reaction mixture was diluted
with 10 mL of Et2 0 and the layers were separated. The clear
organic layer was dried over Na2S04 , filtered, and the 55
solvent was removed under vacuum to afford a clear oil (0.8
g).
The crude product was taken up in 20% EtOAc/hexanes
(due to solubility problems in desired eluent) and purified
via column chromatography (silica gel, 10% EtOAc/ 60
hexanes). R,S-epoxide, as well as a small amount of a
nonpolar impurity, were collected prior to running a gradient
to 50% EtOAc!hexanes to collect the deblocked impurity.
The two fractions were evaporated of solvent to obtain clear
oils: R,S-epoxide: 0.444 g (solidified under vacuum; HPLC: 65
-90%). The identity of the R,S-epoxide was confirmed by
1 H NMR, HPLC, and TLC.
25
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(II)
(I)
with a reducing agent to form an S,S-halomethyl alco-
hol (S,S-HMA) compound having the following gen-
eral formula:
said method comprising:
(a) reducing a halomethyl ketone (HMK) compound
having the following general formula:
and
contacting said R,S-HMA compound of Formula II with
an alkali metal base to form said R,S-epoxide com-
pound;
wherein:
R1 is an amino acid side chain;
R2 is a blocking group; and
Xl is a leaving group.
2. The method in accordance with claim 1, wherein Rl is
an amino acid side chain having a benzyl group; R2 is a BOC
blocking group; and Xl is chloro or bromo.
3. The method in accordance with 1, wherein said non-
chelating, bulky reducing agent is a member selected from
the group consisting of lithium aluminum t-butoxyhydride
(LATBH) and sodium tris-t-butoxyborohydride (STBH).
4. The method in accordance with claim 1, wherein the
reduction is carried out in diethyl ether.
5. The method in accordance with claim 1, wherein said
alkali metal base is a member selected from the group
consisting of NaOH, KOH, LiOH, NaOCH3 , NaOCH2 CH3
and KOtEu.
6. A method for preparing an R,S-epoxide compound
having the following general formula:
50
4. R,S-Epoxide by Alkene Route
A mixture of BOC-alkene (0.498 g, 2.02 mmol), meta-
chloroperbenzoic acid (1.93 g, 8.1 mmol) and dichlo- 20
romethane (22 mL) was stirred at ambient temperature for 3
h at which time HPLC analysis indicated the starting mate-
rial had been consumed. The reaction mixture was quenched
with aqueous 10% Na2S03 (60 mL), and diluted with diethyl
ether. The organic layer was washed with cold saturated 25
Na2 C03 (60 mL), brine (60 mL), dried over Na2S04 , and the
solvent evaporated to provide a clear oil that solidified on
standing. A white solid (0.49 g, 1.86 mmol) was isolated in
92% yield and was shown to be a 5.2:1 mixture of R,S- and
S,S-epoxide, respectively (HPLC, 96.5% pure combined). 30
Analysis of the product mixture by proton NMR spectros-
copy indicated an approximate 5.7:1 ratio of diasteriomeric
epoxides and no alkene starting material.
It is to be understood that the above description is
intended to be illustrative and not restrictive. Many embodi- 35
ments will be apparent to those of skill in the art upon
reading the above description. The scope of the invention
should, therefore, be determined not with reference to the
above description, but should instead be determined with
reference to the appended claims, along with the full scope 40
of equivalents to which such claims are entitled. The dis-
closures of all articles and references, including patent
applications and publications, are incorporated herein by
reference for all purposes.
What is claimed is: 45
1. A method for preparing an R,S-epoxide compound
having the following general formula:
and the filtrate was concentrated in vacuo to give an oil. This
oil was dissolved in ethyl acetate (100 mL) and washed with
2% aqueous acetic acid (50 mL). The organic layer was
separated, dried (Na2S04), filtered and evaporated to give
7.5 g of crude product, an oil; this oil solidified on standing 5
at room temperature to give a white solid. The solid was
dissolved in methylene chloride (50 mL) and the solution
was filtered through 10 g of silica gel. Evaporation of the
solvent gave 6.0 g (77% yield of the desired olefin. HPLC
analysis showed the olefin was >99% pure. BOC-Alkene: lH
10NMR (CDCI3): /) 1.40 (s, 9H), 2.83 (br d, 2H, 1=6.6 Hz),
4.43 (br s, 2H), 4.56 (br s, 2H), 5.06-5.13 (m, 2H, 1=17.4,
10.5,1.2 Hz), 5.8 (ddd, 2H, 1=17.1,10.5,5.4 Hz), 7.20-7.31
(m, 5H); IR (thin film): v 3359 (NH), 1686 (CO), 1645
(alkene); HPLC (Short) tR 3.87 min=0.65%, 4.01 min=
0.04%, 4.69 min=0.19%, 8.38 min=99.12%; MS, me MH+ 15
248.1661.
said method comprising: 55
reducing a halomethyl ketone (HMK) compound having
the following general formula:
(I)
60
with a non-chelating, bulky reducing agent to form an 65
R,S-halomethyl alcohol (R,S-HMA) compound having
the following general formula:
(II)
OH
H~. 1 _Xl
R
I7" "-/
R2HN
(b) contacting said S,S-HMA compound of Formula II
with a member selected from the group consisting of
arylsulfonyl halides and alkylsulfonyl halides in the
presence of an amine to form an S,S-halomethyl sul-
fonyl (S,S-HMS) compound having the following gen-
eral formula:
27
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17. The method in accordance with claim 6, wherein step
(b) is carried out at a temperature ranging from about 10° C.
to about 70° C.
18. The method in accordance with claim 6, wherein said
5 acetate is a member selected from the group consisting of
cesium acetate, potassium acetate, tetrabutylammonium
acetate and sodium acetate.
19. The method in accordance with claim 6, wherein step
(c) is carried out at a temperature ranging from about 20° C.
10 to about 100° C.
20. The method in accordance with claim 6, wherein step
(c) is carried out at a temperature ranging from about 65° C.
to about 75° C.
21. The method in accordance with claim 6, wherein step
(c) is carried out in a solvent selected from the group
consisting of hydrocarbons and chlorinated solvents.
22. The method in accordance with claim 6, wherein step
(c) is carried out in toluene.
23. The method in accordance with claim 6, wherein said
phase transfer catalyst is a member selected from the group
consisting of crown ethers, quaternary ammonium salts and
quaternary phosphonium salts.
24. The method in accordance with claim 6, wherein said
25 phase transfer catalyst is a crown ether.
25. The method in accordance with claim 24, wherein said
phase transfer catalyst is a crown ether.
26. The method in accordance with claim 6, wherein said
water is present in an amount ranging from about 0.5% to
30 about 10%.
27. The method in accordance with claim 6, wherein said
water is present in an amount ranging from about 0.5% to
about 5%.
28. The method in accordance with claim 6, wherein said
alkali metal base is a member selected from the group
consisting of NaOH, KOH, LiOH, NaOCH3 , NaOCH2 CH3
and KOtEu.
29. The method in accordance with claim 6, wherein said
40 (d) is carried out in a solvent selected from the group
consisting of hydrocarbons, chlorinated solvents and THE
30. The method in accordance with claim 29, wherein said
solvent is a mixture of toluence and THE
31. The method in accordance with claim 6, further
45 comprising purifying said R,S-epoxide compound by recrys-
tallization with petroleum ether.
32. The method in accordance with claim 1, wherein said
non-chelating, bulky reducing agent is a member selected
from the group consisting of (+)-Dip Chloride TM,
50 K-Selectride®, KS-Selectride®.
33. The method in accordance with claim 21, wherein said
solvent is a hydrocarbon.
34. The method in accordance with claim 33, wherein said
hydrocarbon is an aromatic hydrocarbon.
35. The method in accordance with claim 29, wherein said
solvent is a hydrocarbon.
36. The method in accordance with claim 35, wherein said
hydrocarbon is an aromatic hydrocarbon.
(III)
(IV) 15
(c) contacting said S,S-HMS compound of Formula III
with an acetate in the presence of a phase transfer
catalyst and water to form an R,S-halomethyl acetate
(R,S-HMAc) compound having the following general
formula:
and (d) contacting said R,S-HMAc compound of For-
mula IV with an alkali metal base to form said R,S-
epoxide;
wherein:
R1 is an amino acid side chain;
R2 is a blocking group;
R3 is a member selected from the group consisting of
arylsulfonyls and alkylsulfonyls;
R4 is an acyl group; and
Xl is a leaving group.
7. The method in accordance with claim 6, wherein R l is
an amino acid side chain having a benzyl group; R2 is a BOC
blocking group; and Xl is chloro or bromo.
8. The method in accordance with claim 6, wherein R3 is 35
a member selected from the group consisting of
methylsulfonyl, toluenesulfonyl, trifiuoromethanesulfonyl
and para-nitrobenzenesulfonyl.
9. The method in accordance with claim 6, wherein R4 is
an acetyl group.
10. The method in accordance with claim 6, wherein said
reducing agent is a member selected from the group con-
sisting of sodium borohydride, lithium aluminum hydride
and sodium cyanoborohydride.
11. The method in accordance with claim 6, wherein step
(a) is carried out in a solvent selected from the group
consisting of ethanol, methanol, isopropanol, THF and
diethyl ether.
12. The method in accordance with claim 6, wherein step
(a) is carried out at a temperature ranging from about _30°
C. to about room temperature.
13. The method in accordance with claim 6, wherein said
amine is triethylamine.
14. The method in accordance with claim 6, wherein step
(b) is carried out in a solvent selected from the group
consisting of chlorinated solvents, ethyl acetate, ethers and 55
aromatic hydrocarbons.
15. The method in accordance with claim 6, wherein step
(b) is carried out in toluene.
16. The method in accordance with claim 6, wherein step
(b) is carried out at a temperature ranging from about _30°
C. to about 100° C.
